PMID- 32132063
OWN - NLM
STAT- MEDLINE
DCOM- 20200415
LR  - 20231213
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 40
IP  - 3
DP  - 2020 Mar
TI  - Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment 
      of Metastatic Colorectal Cancer.
PG  - 1605-1611
LID - 10.21873/anticanres.14108 [doi]
AB  - BACKGROUND/AIM: The aim of this study was to clarify the risk benefits of folinic 
      acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) as 
      third-line and later-line treatment for metastatic colorectal cancer (mCRC). 
      PATIENTS AND METHODS: We compared the overall survival (OS), adverse events 
      (AEs), and cost of F-RAM to those of trifluridine/tipiracil combination tablet 
      (TAS-102). RESULTS: There was no significant difference in the median OS [6.1 
      (range=1.2-16.3) months vs. 6.1 (range=1.2-22.3) months; log-rank test, p=0.272] 
      and treatment duration [4.0 (range=1.2-9.6) months vs. 3.5 (range=0.2-12.3) 
      months, p=0.888] between the F-RAM (n=13) and the TAS-102 (n=36) groups. However, 
      AEs were more frequent in the F-RAM group, and 1-year administration of F-RAM 
      cost higher ($81,724.8 vs. $18,931.4, p<0.001). CONCLUSION: F-RAM as third-line 
      and later-line treatment for mCRC has a poor risk benefit. TAS-102 should be 
      given priority over F-RAM.
CI  - Copyright(c) 2020, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kimura, Michio
AU  - Kimura M
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan 
      kimkim0305nao@yahoo.co.jp.
FAU - Usami, Eiseki
AU  - Usami E
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
FAU - Teramachi, Hitomi
AU  - Teramachi H
AD  - Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
FAU - Yoshimura, Tomoaki
AU  - Yoshimura T
AD  - Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 7673326042 (Irinotecan)
RN  - Q573I9DVLP (Leucovorin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy/mortality/pathology
MH  - Female
MH  - Fluorouracil/pharmacology/*therapeutic use
MH  - Humans
MH  - Irinotecan/pharmacology/*therapeutic use
MH  - Leucovorin/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Survival Rate
MH  - Ramucirumab
OTO - NOTNLM
OT  - Ramucirumab
OT  - adverse event
OT  - drug cost
OT  - metastatic colorectal cancer
OT  - overall survival
OT  - third-line treatment
EDAT- 2020/03/07 06:00
MHDA- 2020/04/16 06:00
CRDT- 2020/03/06 06:00
PHST- 2019/12/03 00:00 [received]
PHST- 2020/02/04 00:00 [revised]
PHST- 2020/02/05 00:00 [accepted]
PHST- 2020/03/06 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2020/04/16 06:00 [medline]
AID - 40/3/1605 [pii]
AID - 10.21873/anticanres.14108 [doi]
PST - ppublish
SO  - Anticancer Res. 2020 Mar;40(3):1605-1611. doi: 10.21873/anticanres.14108.